FLX 787
Alternative Names: FLX-787-ODT; FLX787Latest Information Update: 08 Oct 2021
At a glance
- Originator Flex Pharma
- Developer Flex Pharma; Salarius Pharmaceuticals
- Class Antispastics; Muscle relaxants; Small molecules
- Mechanism of Action TRPA1 protein stimulants; TRPV cation channel agonists; TRPV1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Multiple sclerosis
- No development reported Deglutition disorders
- Discontinued Amyotrophic lateral sclerosis; Charcot-Marie-Tooth disease; Motor neuron disease; Neuromuscular disorders
Most Recent Events
- 08 Oct 2021 FLX 787 is still in phase II trials in Multiple sclerosis in Australia (Flex Pharma pipeline, October 2021)
- 28 Jul 2021 No recent reports of development identified for clinical-Phase-Unknown development in Deglutition-disorders in Unknown (PO)
- 22 Jul 2019 Flex Pharma merged with Salarius Pharmaceuticals to form Salarius Pharmaceuticals